Team

Megan Golden is the co-founder and CEO of Mission: Cure, which is using outcome-based financing and impact investing to demonstrate a new model for curing disease, beginning with chronic pancreatitis, a devastating disease afflicting her younger brother. She also serves as a Voting Member of the Institute for Clinical and Economic Review (ICER) New England Comparative Effectiveness Public Advisory Council, which provides independent appraisals of the benefits and costs of medications and other health interventions.

Megan has 25 years of experience developing and launching innovative programs in multiple fields including criminal justice, child welfare, mental health, and eldercare, as a senior executive at the Vera Institute of Justice and at the Institute for Child Success. Significant projects include helping South Carolina use Pay for Success financing to fund a $30 million expansion of early childhood services to low-income families (the largest Pay for Success project in the world), leading a major reform of New Orleans’ criminal justice system in the wake of Hurricane Katrina, and creating a successful alternative to detention for people in immigration proceedings.

Megan has also published extensively on Pay for Success financing and performance measurement. She served on McKinsey & Company’s advisory group for its work on Social Impact Bonds, and as a Fellow at the New York University Wagner Graduate School of Public Service, where she taught performance management and directed the Fellowship for Emerging Leaders in Public Service.

In 1994, Megan was awarded a White House Fellowship. She has a BA in political science from Brown University and a JD, magna cum laude, from the New York University School of Law.

Lola Rahib oversees Mission: Cure’s scientific efforts to drive development of the most promising and effective therapies for pancreatitis.

She has extensive experience in strategically leading and bringing scientific and clinical programs to success. Prior to joining Mission: Cure, she was the Director of Scientific and clinical affairs at Cancer Commons, where she led the development and implementing of a Virtual Tumor Board (VTB) program with a knowledge base learning system for pancreatic cancer patients.
At the Pancreatic Cancer Action Network, she led scientific research and initiatives including a molecular profiling program, a patient registry, and an early detection initiative. In addition, she has authored many publications that have contributed to the field of pancreatic cancer.

She also spent a few years in the private sector as a scientist for multiple biotech companies. Lola has an undergraduate degree in biochemistry and an MS and PhD in biomedical engineering from UCLA.

Skye Shrader oversees Mission: Cure’s digital marketing and communication strategies as our Creative Communications Manager. She is responsible for engaging patients, families, researchers, clinicians, and other members of Mission: Cure’s community by providing useful, timely information and opportunities for interaction and connection.

Prior to joining Mission: Cure, Skye served as a Graphic Designer and Digital Marketing Assistant at Back40 Design. There, she was responsible for the ideation and execution of branding, print and digital design, and marketing campaigns for small and large businesses.

Skye has also played a key role in developing the brand strategies of several nonprofit organizations, such as Circle of Care, a foster care and prevention resources agency, and Out of Harm’s Way OKC, a needle exchange and harm reduction organization serving Oklahoma. She is passionate about creating lasting impact in communities that have historically been underserved.

Skye is a graduate of the University of Oklahoma, where she earned a B.A. in Journalism, with a focus in Advertising.

Eric Golden is an investment banker, entrepreneur, and advocate for those coping with pancreatic disease. After being diagnosed with chronic pancreatitis in 2012 and witnessing the often-tragic toll of the disease, he decided to make fighting such conditions a life focus. He is a co-founder of Mission: Cure, an organization dedicated to finding a cure for pancreatitis within 10 years; Chairman of the Collaborative Alliance for Pancreatic Education and Research (CAPER); and a board member of the National Pancreas Foundation. He has testified in front of the FDA and regularly speaks to patients, physicians and researchers about his experience with pancreatic disease.
Professionally, Eric is the Founder and Managing Director of Fluential Partners, a boutique investment bank, Chairman of mobility startup Exokinetics, and a board member of several other ventures. Previously, he has served in roles ranging from CEO of a startup to General Counsel of Panavision and the Washington Football Team. Eric earned a J.D. from Harvard Law School and an A.B. from Brown University.

Linda Martin has been a serial entrepreneur, corporate executive, consultant, and board member for more than 30 years. She has launched, managed and advised dozens of companies in the mobile telecom and “Internet of Things” industries. Linda is the founder and president of Martin Strategic Solutions helping early and growth stage companies with corporate/business development, creating and implementing new strategies and making introductions to strategic partners and customers in the US and abroad. She has also conceived and coordinated a successful impact investment in innovative cancer research and therapies.

In mid-2017, Linda’s daughter was diagnosed with Chronic Pancreatitis and Linda began researching available treatments and cures. She quickly discovered that pancreatitis is not widely understood and that there is a need for new approaches and models to discover more effective treatments with better outcomes. Linda also saw an urgent need for advocacy, funding, research, education and collaboration in the mission to find a cure to enable pancreatitis patients to live better, healthier lives.

Dr. Bruce Bloom is Chief Collaboration Officer at Healx, which brings sensibly-priced repurposed therapies to rare disease patient communities using artificial and human intelligence in new ways. Until 2019, he was Chief Executive Officer of Cures Within Reach, a nonprofit saving lives by repurposing human approved drugs, devices, diagnostics and nutraceuticals to quickly deliver safe and affordable treatments and cures for diseases that have no currently effective therapy. Cures Within Reach uses CureAccelerator™, the only global online repurposing research collaboration platform, to bring together clinicians, researchers, funders, and industry to create and conduct pilot clinical trials that drive more treatments to more patients more quickly.

Dr. Bloom became an Ashoka Social Entrepreneur Fellow for his system-changing solutions to finding new treatments for unsolved diseases. He is the Patient Advisory Board Chair for the Institute for Translational Medicine, Board member of the Drug Discovery Center at the University of Illinois, the Director of Scientific Affairs for Vision for Tomorrow, on the Science Advisory Boards of Rediscovery Life Sciences, the GARROD AKU Consortium, the Dr. Ralph and Marian Falk Medical Research Trust Awards Programs, the Findacure Fundamental Disease Charity, and Healx, LTD, is the Chair of the Governance Committee of the Kendall College Charitable Trust, is a member of the Board of Councilors of Midwestern University, and a member of the editorial board of ASSAY and Drug Development Technologies. Dr. Bloom holds a Juris Doctor degree from the IIT Chicago-Kent College of Law, a Doctor of Dental Surgery degree from University of Illinois Medical Center, and a Bachelor of Science degree in Biology from University of Illinois. He is an adjunct faculty member at Kendall College, has been a lecturer at the University of Illinois Chicago since 1990, and was a senior lecturer at Northwestern University Dental School for 6 years.

Mickey Levitan is currently serving as a Visiting Fellow at the Indiana University Lilly Family School of Philanthropy, where he is conducting R&D for an innovative program to enable promising nonprofits to tackle perennial organizational development and financial challenges that limit broader impact and sustainability. Before joining the School of Philanthropy, Mickey was Founder and CEO of an educational technology company undertaking a major system change effort to shape the way digital course materials are used in higher education.

Mickey has served as Executive Vice President and Chief Human Resources Officer for Emmis Communications, Director of Human Resources for Apple, and Executive Director for Organizational Effectiveness at Cummins Inc., building world-class workplaces recognized in numerous “Best Places to Work” awards. Mickey’s early career was spent with Peace Corps in Africa and directing the Save the Children program in Thailand. Returning from overseas, Mickey served as a White House Fellow, working in the office of the Vice President.

Mickey received his Bachelor of Arts with high distinction from Dartmouth College. He attended Stanford University and earned an MBA from the Graduate School of Business, an MA from the Stanford Food Research Institute and was selected by his MBA classmates as the Arbuckle Award winner for outstanding contribution. In addition to speaking a wee bit of English, Mickey has gained fluency in four other languages: French, Thai, Bengali, and Wolof.

Jim Medsker is the owner and president of Keystone Solutions Group, a turn-key medical device development and contract manufacturing company located in Kalamazoo, MI. The Keystone journey began in 1998 and over the last 24+ years the company has helped launch a wide range of Class I and Class II devices in wound care, imaging, diagnostics, and many other areas. Jim also serves as an advisor and board member for a number of companies and non-profit organizations and holds a Master of Science degree in Mechanical Engineering from Western Michigan University.

Professor Bruce Aronow is the John Hutton MD Professor of Biomedical Informatics and Co-director of the Computational Medicine Center at Cincinnati Children’s and has developed a computable data model network for chronic pancreatitis that helped determine which drugs were most likely to correct the biological problems causing pancreatitis. The model links known genetic mutations to biological pathways and the gene signature of pancreatic cell types using Mouse and Human Single Cell Atlas data. These normal gene networks could then be connected to disease mechanisms and therapeutic targets to improve identification of drugs could increase or decrease risks of the causes and symptoms of chronic pancreatitis.

Dr. Aronow earned his BS in Chemistry at Stanford University in 1976 and his PhD in Biochemistry at the University of Kentucky in 1986. He completed his Research Fellowship at the Division of Basic Science Research, Cincinnati Children’s Research Foundation from 1986 to 1989. His patents include CFTR modifier genes and expressed polypeptides useful in treating cystic fibrosis and methods and products for detecting and/or identifying same and Altered gene expression profiles in stable versus acute childhood asthma.

Dr. Melena Bellin is a leading expert on islet transplantation for patients with Type 1 diabetes mellitus and those who have had their pancreas removed to treat chronic pancreatic disease, including chronic pancreatitis. Dr. Bellin is Associate Professor of Pediatrics and Associate Professor of Surgery at the University of Minnesota Medical School, where she completed medical school, pediatric residency and pediatric and endocrine fellowships. She also completed a Masters in Science in Clinical Research at the University of Minnesota’s School of Public Health. Dr. Bellin has published extensively on the subject of TPIAT, islet transplantation and advances in diabetes research and a frequent presenter at medical conferences around the world. Dr. Bellin has been recognized as an Innovator in Translational Research and is greatly admired and beloved by both her adult and pediatric patients.

Dr. Ford-Hutchinson is currently a Board Member or Scientific Advisor to multiple startup companies, including the position of CSO of Rbonova Inc, as well as not for profit organizations including the Hepatitis B Foundation, SAGE Bionetworks, the Wellcome Trust, CARB-X and CEPI. Tony has over 40 years of experience in pharmaceuticals, including an extensive tenure at Merck & Co. At Merck Frosst, Canada, Tony led teams that developed Singulair®, Cox-2 inhibitors (Vioxx® and Arcoxia®), prostaglandin DP receptor antagonist (a component of Tredaptive®) and Cat K inhibitors (odanacatib) making the Merck Frosst Laboratories the most productive discovery unit of Merck. Subsequent career highlights at Merck relating to infectious disease include the development of HIV integrase inhibitor Isentress® and development & licensing of therapies to tackle drug-resistant bacterial infections. Tony’s most recent responsibility at Merck as head of Vaccine R&D led to the commercialization of 4 vaccines; Gardasil®, Zostavax®, Proquad® and Rotateq®. Tony is a Trustee of the International Vaccine Institute.

Dr. Mark Haupt, MD is the Chief Medical Officer at International Flavors & Fragrances. Dr. Haupt is a Pediatric Pulmonologist who has dedicated his career to helping patients with pancreatic disease through his work in academia, the pharmaceutical industry, and his prior work with Ariel Precision Medicine. Dr. Haupt was previously with AbbVie Pharmaceuticals, quickly accelerating from their Physician Professional Development Program to a leadership role in the US Medical Affairs organization and earning the President’s Award. He completed a residency in general pediatrics at the University of Chicago Medical Center, earning intern and resident of the year awards. After serving an additional year as Chief Resident, Dr. Haupt completed a fellowship in Pediatric Pulmonary Medicine at the Ann & Robert H. Lurie Children’s Hospital of Chicago. His research focus was cystic fibrosis, specifically examining epidemiological data to evaluate nutritional outcomes.

Stephen Pandol, MD, is Director of Basic and Translational Research at Cedars-Sinai Medical Center and Professor of Medicine, University of California Los Angeles. His career has been devoted to understanding the mechanisms of pancreatic diseases, both inflammatory and malignant. He leads lab based studies using mechanistic understanding to develop new therapeutics and clinical projects at the local and national level to test prevention and treatment strategies for pancreatic diseases. Dr. Pandol attended medical school at Saint Louis University School of Medicine. Click here for more on Dr. Pandol.

Dr. Ashok Saluja obtained his doctoral degree in Biochemistry from Washington State University in 1980. After a post-doctoral stint at Cornell University, he joined Harvard Medical School where he rose to the rank of Associate Professor in Surgery. After twenty years at Harvard, he joined University of Massachusetts Medical School as Professor of Surgery, Medicine and Cell Biology and Director of Pancreatic Diseases Center. In 2006, he joined the faculty of the Department of Surgery at the University of Minnesota Medical School as Professor and Vice Chair. He also held the Sit Family Chair in Pancreatic and GI cancer research. The University of Minnesota conferred him McKnight Presidential Endowed Chair in 2014, one of the highest honors in the university. In 2016 Dr. Saluja relocated to University of Miami as Professor and Vice Chair of Research and Faculty Development of Surgery, Senior Associate Dean for Research, and Director of the Sylvester Pancreatic Cancer Research Institute. Dr. Saluja’s research focuses on understanding the physiology of the pancreas and the pathophysiology of pancreatic diseases. He is internationally renowned for his work on the pathogenesis of pancreatitis. His group has recently shown that pancreatic tumors overexpress Heat Shock Protein 70 and its inhibition causes death of these cells not only in in vitro settings but also in mouse models of pancreatic cancer. Dr. Saluja’s group has developed a novel drug, which they have named Minnelide (due to its origin from Minnesota).

Dr. Saluja has published more than 160 original research papers in peer-reviewed international journals along with several review articles and book chapters. His research has been funded by the National Institute of Health (NIH) and several biotechnology companies in addition to philanthropic support. Additionally, he is an inventor on several patents. He is one of the largest NIH-funded investigators at the University of Miami. He also is CSO and co-founder of a start-up biotechnology company Minneamrita Therapeutics. Over the years Dr. Saluja has been invited to give numerous state-of-the art lectures and keynote addresses at national and international meetings. He has served on NIH panels and the editorial boards of several scientific journals. He is currently Associate Editor of Gastroenterology. He is the past president of American Pancreatic Association (APA) and International Association of Pancreatology (IAP). He is currently Secretary-Treasurer of American Pancreatic Association. Dr. Saluja was honored with the prestigious George Palade Award by IAP in 2013, a lifetime achievement award by the APA in 2014, and a medal from the Australian Society of Medical Research in 2015.

Professor David C. Whitcomb MD PhD is the Giant Eagle Foundation Professor of Cancer Genetics, a Professor of Medicine (with tenure), Cell Biology and Physiology, and Human Genetic and Director of the Precision Medicine Service at UPMC. He is editor-in-chief of Clinical and Translational Gastroenterology, the top ranked open access gastroenterology and hepatology journal. Dr. Whitcomb leads active research teams focusing on pancreatic diseases, and provides an information service on pancreas-related issues to patients, physicians, and scientist through publications, lectures and contributions to Pancreas.org, and a quarterly patient newsletter, Pancreas Education and Research Letter (PEaRL). Professor Whitcomb’s research and discoveries resulted in a major paradigm shift in understanding inflammatory disease of the pancreas. His work on pancreatic diseases as a complex gene-environment disorder also resulted in major advances in a paradigm for personalized medicine (Nat Rev Gastroenterol Hepatol. 2012;9(7):418-24). Prof. Whitcomb graduated from Manchester University, North Manchester, Indiana, in 1978 with a BS in Biology/Chemistry. Continuing his education, he received a MS in Physiology in 1979, a PhD in Physiology in 1983, and an MD in 1985 all from the Ohio State University, Columbus, Ohio. He then completed a residency in internal medicine in 1988, followed by a fellowship in gastroenterology in 1991 at Duke University, Durham, North Carolina.